Response to systemic therapy in locally advanced and metastatic renal cell carcinoma: can it be predicted?

Abstract:

INTRODUCTION:: Renal cell carcinoma is no longer considered a monolithic disease, but a group of different entities exhibiting unique molecular alterations requiring a tailored systemic approach. One of the remaining challenges is the identification of the best candidate for a particular therapeutic regimen. AREAS COVERED:: Current literature regarding the recent advances and treatment options in systemic therapy for metastatic RCC, and issues pertaining to the available biomarkers tested to date for a correct treatment stratification. EXPERT OPINION:: Underlying biology of RCC will still drive the development of new treatment agents/combinations that will be tested in earlier stages of the disease, and probably prove to have a role in the neoadjuvant/adjuvant settings. The correct characterization of the tumor microenvironment through transcriptomic analysis should help to overcome the issues related to tumor heterogeneity. Preclinical ex-vivo models will enlarge our current knowledge regarding the potential immune-escape mechanisms exhibited by RCC, and facilitate a better monitoring of the response to therapy. New tracers, image modalities, and tests aimed at detecting and analyzing tumor-circulating cells will improve our clinical performance through a better identification of the metastatic site locations and their variable histologic patterns, and ultimately their behavior in response to treatment.

authors

González J,Gaynor JJ,Ciancio G

doi

10.1080/14737140.2021.1878882

subject

Has Abstract

pub_date

2021-01-29 00:00:00

pages

1-11

eissn

1473-7140

issn

1744-8328

pub_type

杂志文章
  • Treatment of newly diagnosed diffuse brain stem gliomas in children: in search of the holy grail.

    abstract::Diffuse brain stem glioma is the most devastating of pediatric malignancies. Virtually all children with this disease die within 1-2 years of diagnosis. After three decades of exhaustive research, the key to controlling this malignancy still eludes us. Attempts to improve survival using radiation, chemotherapy and bio...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.5.663

    authors: Korones DN

    更新日期:2007-05-01 00:00:00

  • Is axillary dissection needed in node-positive breast cancer?

    abstract::The standard of care in the management of the axilla for a woman with breast cancer was traditionally a level I and II axillary lymph node dissection (ALND). Since the pivotal studies in the mid-1990s, sentinel lymph node biopsy (SLNB) in breast carcinoma has come to replace ALND in women with clinically negative axil...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.8.2.195

    authors: Greenberg CC,Bafford AC,Golshan M

    更新日期:2008-02-01 00:00:00

  • Oncolytic viruses: a novel form of immunotherapy.

    abstract::Oncolytic viruses are novel anticancer agents, currently under investigation in Phase I-III clinical trials. Until recently, most studies have focused on the direct antitumor properties of these viruses, although there is now an increasing body of evidence that the host immune response may be critical to the efficacy ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.10.1581

    authors: Prestwich RJ,Harrington KJ,Pandha HS,Vile RG,Melcher AA,Errington F

    更新日期:2008-10-01 00:00:00

  • Highlights of the 2nd European Lung Cancer Conference.

    abstract::The Second European Lung Cancer Conference was held in Geneva, Switzerland from 28 April to 1 May 2010, under the cosponsorship of the International Association for the Study of Lung Cancer and the European Society for Medical Oncology. The main topics included: tobacco control, which represents a crucial challenge fo...

    journal_title:Expert review of anticancer therapy

    pub_type:

    doi:10.1586/era.10.93

    authors: Girard N,Mornex F

    更新日期:2010-07-01 00:00:00

  • Update on genetic predisposition to breast cancer.

    abstract::It has been evident for some time that individuals from some families exhibit a genetic predisposition to breast cancer. Since the discovery of the first breast cancer susceptibility gene, BRCA1 in the 1990s, much work has been carried out to identify further breast cancer susceptibility genes. This has led to the ide...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.38

    authors: Ahmed M,Lalloo F,Evans DG

    更新日期:2009-08-01 00:00:00

  • Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.

    abstract::Introduction: Small-cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumour, and its outcome is strongly conditioned by the rapid onset of resistance to conventional chemotherapeutics. First-line treatment with a combination of platinum agents and topoisomerase inhibitors has been the standard of care for...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1624530

    authors: Van Den Borg R,Leonetti A,Tiseo M,Giovannetti E,Peters GJ

    更新日期:2019-06-01 00:00:00

  • Colorectal cancer: using blood samples and tumor tissue to detect K-ras mutations.

    abstract::We performed a meta-analysis to assess whether blood can be substituted for tumor tissue in K-ras mutation testing. PubMed, EMBASE, MEDLINE, and BIOSIS databases were searched. Twenty-three studies including 1261 patients were included. The pooled overall sensitivity, specificity, and concordance rate were 0.69 (95% C...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,meta分析

    doi:10.1586/14737140.2015.1037836

    authors: Li Y,Fu XH,Yuan JQ,Yang ZY,Mao C,Dong XM,Tang JL,Wang SY

    更新日期:2015-06-01 00:00:00

  • Medical approaches to non-melanoma skin cancer.

    abstract::Medical therapy represents an alternative treatment approach that can be considered for some forms of non-melanoma skin cancer (NMSC). In selected cases, topical treatments are preferable to invasive procedures, especially in the case of multifocal lesions, unclear lesion edges, risk of keloids, surgical risk factors ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.856759

    authors: Micali G,Lacarrubba F,Bhatt K,Nasca MR

    更新日期:2013-12-01 00:00:00

  • Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy.

    abstract::Renal neoplasms exhibit a wide spectrum of molecular characteristics that are closely associated with their diverse morphologic manifestations and clinical behaviors. A wealth of information has been garnered via methodology ranging from classical cytogenetics to FISH and gene expression profiling; however, the exact ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.72

    authors: Cheng L,Williamson SR,Zhang S,Maclennan GT,Montironi R,Lopez-Beltran A

    更新日期:2010-06-01 00:00:00

  • The multidisciplinary management of giant cell tumor of bone.

    abstract::Giant cell tumor of bone is a locally aggressive lesion with a predilection for local recurrence, and in a small proportion of patients, metastatic disease can develop. Surgery is the mainstay of management for extremity-based lesions. For tumors located in challenging anatomical locations such as the sacrum and spine...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.901891

    authors: Ng VY,Davidson DJ,Kim EY,Pollack SM,Conrad Iii EU,Jones RL

    更新日期:2014-07-01 00:00:00

  • Salvage of local recurrence after primary thermal ablation for small renal masses.

    abstract::The management of renal tumors has evolved rapidly over the last two decades, with the ascendance of nephron-sparing surgery (NSS), largely spurred by the increased incidental detection of small renal masses (SRMs) and evidence that preservation of renal parenchyma reduces the risk of chronic kidney disease. The field...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.12.1899

    authors: Nguyen CT,Campbell SC

    更新日期:2008-12-01 00:00:00

  • Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions.

    abstract:INTRODUCTION:The aim of this paper was to perform a narrative review of the literature on the available approaches in the treatment of two emerging subpopulations of metastatic renal cell carcinoma (mRCC) patients: the oligometastatic disease (less than 5 metastasis) and the oligoprogressive disease, defined as worseni...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2020.1770601

    authors: Donini M,Buti S,Massari F,Mollica V,Rizzo A,Montironi R,Bersanelli M,Santoni M

    更新日期:2020-06-01 00:00:00

  • Raloxifene for the treatment and prevention of breast cancer?

    abstract::Raloxifene is a member of a family of drugs known as selective estrogen receptor modulators (SERMs). Raloxifene is currently approved by the FDA for the prevention and treatment of osteoporosis in postmenopausal women. SERMs hold the potential to treat and prevent breast cancer, osteoporosis and coronary heart disease...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.1.3.334

    authors: Pappas SG,Jordan VC

    更新日期:2001-10-01 00:00:00

  • Aromatase inhibitors in breast cancer therapy.

    abstract::Estrogens are involved in numerous physiological processes and have crucial roles in certain disease states, such as mammary carcinomas. Estradiol, the most potent endogenous estrogen, is biosynthesized from androgens by the cytochrome P450 enzyme complex called aromatase. Aromatase is found in breast tissue and the i...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2.2.181

    authors: Brueggemeier RW

    更新日期:2002-04-01 00:00:00

  • Surgical oncology in the age of multimodality therapy for cancer of the upper and lower gastrointestinal tract.

    abstract:INTRODUCTION:To date, all efforts to fight gastrointestinal cancer, regardless of its origin and entity, have resulted in complex therapeutic regimens involving a combination of systemic therapy, radiation therapy and surgery. It is generally accepted across all disciplines that not one, but the combination and the pro...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1868991

    authors: Neumann PA,Berlet MW,Friess H

    更新日期:2021-01-08 00:00:00

  • Screening for ovarian cancer.

    abstract::Ovarian cancer frequently presents late, when chances for long-term survival are poor. The increased survival advantage for patients diagnosed with early-stage ovarian cancer suggests that screening to detect early-stage disease might have an impact on disease mortality. Attempts are being made to develop effective sc...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.1.55

    authors: Lewis S,Menon U

    更新日期:2003-02-01 00:00:00

  • Targeted therapy for metastatic colorectal cancer.

    abstract:INTRODUCTION:Outcomes in metastatic colorectal cancer are improving, with better understanding and use of targeted therapies. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This article reviews the current ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1502664

    authors: Price TJ,Tang M,Gibbs P,Haller DG,Peeters M,Arnold D,Segelov E,Roy A,Tebbutt N,Pavlakis N,Karapetis C,Burge M,Shapiro J

    更新日期:2018-10-01 00:00:00

  • Adopting an alternative structure for clinical trials in immunotherapy.

    abstract::Background: This evaluation emphasizes the main points of the original article 'Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies' by Sprenger et al. and provides further justification for the use of an alternative approach in the design...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1875822

    authors: Roussos Torres ET,Epstein AL

    更新日期:2021-01-19 00:00:00

  • Emerging data on improving response to hormone therapy: the role of novel targeted agents.

    abstract:INTRODUCTION:Hormone receptor positive (HR+) breast cancer represents the most common subtype of breast cancer. Metastatic HR+ breast cancer may develop resistance to standard hormone therapies, arising from genomic alterations in the estrogen receptor and/or upregulation of other signal transduction pathways. Areas co...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1412259

    authors: Vidula N,Rugo HS

    更新日期:2018-01-01 00:00:00

  • Role of PET/PET-CT in the management of sarcomas.

    abstract::Positron emission tomography (PET) is a functional diagnostic imaging technique that provides very different information from that obtainable with other imaging modalities. The most widely used radiotracer is F-18 fluoro-2-deoxy-D-glucose (FDG), which is an analog of glucose. The FDG uptake in cells is directly propor...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.8.1241

    authors: Kumar R,Chauhan A,Vellimana AK,Chawla M

    更新日期:2006-08-01 00:00:00

  • Unresolved issues in diffuse large B-cell lymphomas.

    abstract::For more than 25 years, the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was considered the 'gold standard' for the treatment of aggressive lymphomas, 90% of which are diffuse large B-cell lymphomas (DLBCLs). After the demonstration of rituximab's single-agent activity in DLBCL, a pi...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.170

    authors: Murawski N,Zwick C,Pfreundschuh M

    更新日期:2010-03-01 00:00:00

  • Targeting RANKL in breast cancer: bone metastasis and beyond.

    abstract::In breast cancer, RANK ligand (RANKL) appears to play an important role in the process of chemotaxis between circulating tumor cells and the bone microenvironment, which enables RANK-expressing breast cancer cells to migrate into the bone. Mounting clinical evidence has further demonstrated that the anti-RANKL monoclo...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.177

    authors: Azim H,Azim HA Jr

    更新日期:2013-02-01 00:00:00

  • Cladribine in indolent non-Hodgkin's lymphoma.

    abstract::Before the advent of rationally designed targeted antineoplastic therapies, cladribine was identified as a lymphocyte-specific cytotoxic agent. Cladribine is a purine nucleoside analogue that is resistant to cellular catabolism. Through diverse mechanisms, cladribine is equally toxic to dividing and nondividing cells,...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.4.535

    authors: Sigal DS,Saven A

    更新日期:2008-04-01 00:00:00

  • Lymph node dissection for bladder cancer: the issue of extent and feasibility in the minimally invasive era.

    abstract::Lymph node dissection in bladder cancer is an integral part of radical cystectomy. It allows for accurate staging of the patient and will, therefore, serve to dictate additional treatment and add prognostic information. The issue of what is an adequate lymphadenectomy as to the extent and boundaries of the operation, ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.147

    authors: Ghavamian R,Hakimi AA

    更新日期:2009-12-01 00:00:00

  • Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.

    abstract:INTRODUCTION:Metastatic prostate cancer is a life-threatening disease and an important public health concern with prevalence rates varying drastically between high- and low-income countries. Androgen-deprivation therapy alone has been the first-line treatment option for decades, temporarily controlling disease until in...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2020.1785289

    authors: Manceau C,Mourey L,Pouessel D,Ploussard G

    更新日期:2020-08-01 00:00:00

  • Systemic therapy for recurrent endometrial cancer: a review of North American trials.

    abstract::While early-stage endometrial cancer is highly curable after hysterectomy for the majority of patients afflicted with this disease, recurrent and metastatic endometrial cancer continues to pose a significant challenge. The median survival of women with advanced or recurrent uterine cancer on most recent clinical trial...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.54

    authors: Dellinger TH,Monk BJ

    更新日期:2009-07-01 00:00:00

  • Optimal management of pulmonary metastases from colorectal cancer.

    abstract::The incidence of colorectal cancers is rising worldwide and pulmonary metastases were seen in approximately 10-15% of all patients. Surgical metastasectomy is a widely accepted procedure in selected patients and is considered as the only curative option in patients with secondary pulmonary malignancy. But surgical res...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.123

    authors: Limmer S,Unger L

    更新日期:2011-10-01 00:00:00

  • Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer.

    abstract::Colorectal cancer (CRC) is the third most common malignancy and cause of death from cancer among adults worldwide. In recent years, the use of 5-fluorouracil-based regimens in combination with molecularly targeted agents has greatly expanded treatment options for patients with metastatic disease. With a more capillary...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.837667

    authors: Ribecco AS,Pino MS,Cipriani G,Marinozzi C,Fioretto L

    更新日期:2013-10-01 00:00:00

  • Therapeutic approaches for refractory germ cell cancer.

    abstract:INTRODUCTION:Most germ cell cancer patients with metastatic disease are cured by cisplatin-based combination chemotherapy. 30% of metastatic patients will develop relapse or progress despite adequate first-line treatment and will require salvage therapy, with about 10% of metastasized patients ultimately developing pla...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1450630

    authors: Oing C,Seidel C,Bokemeyer C

    更新日期:2018-04-01 00:00:00

  • Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management.

    abstract:INTRODUCTION:Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of breast or ovarian carcinoma. STIC is a pa...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2016.1247699

    authors: Weinberger V,Bednarikova M,Cibula D,Zikan M

    更新日期:2016-12-01 00:00:00